SARPODEX
DEAD

Serial Number

87195772

Owner

EXCIVA UG (haftungsbeschränkt)

Attorney

SREENIVASARAO VEPACHEDU

First Use Date

Jul 2, 2018

Filing Date

Oct 6, 2016

Add to watchlist:

No watchlists yet
View on USPTO

SARPODEX Trademark

Serial Number: 87195772 • Registration: 5656270

SARPODEX is a trademark filed by EXCIVA UG (haftungsbeschränkt) on October 6, 2016. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

EXCIVA UG (haftungsbeschränkt) (6 trademarks)

1230 GEORGETOWN WAY
VERNON HILLS, IL 60061

Entity Type: 16

EXCIVA GMBH (5 trademarks)

1230 GEORGETOWN WAY
VERNON HILLS 69118 , DE

Entity Type: 27

Trademark Details

Filing Date

October 6, 2016

Registration Date

January 15, 2019

First Use Anywhere

July 2, 2018

First Use in Commerce

July 2, 2018

Published for Opposition

September 19, 2017

Cancellation Date

July 25, 2025

Goods & Services

Medical diagnostic reagents and assays for testing of body fluids; Medical diagnostic reagents for the analysis of body fluids; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents for epidermis; Pharmaceutical agents for treating physically caused lesions; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical antitussive-cold preparations; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparation for skin care; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for animal skincare; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical preparations for reducing sexual activity; Pharmaceutical preparations for skin care; Pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system; for the treatment of inflammatory disorders; for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti - infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; Pharmaceutical preparations for the prevention of disorders of the nervous system including central nervous system (CNS) and peripheral nervous system (PNS), peripheral nerve disorders, and mental, neurological, psychological, psychosomatic, posttraumatic stress, alcohol, nicotine, and drug dependence related diseases, disorders and conditions; Pharmaceutical preparations for the treatment of disorders of the nervous system including central nervous system (CNS) and peripheral nervous system (PNS), peripheral nerve disorders, and mental, neurological, psychological, psychosomatic, posttraumatic stress, alcohol, nicotine, and drug dependence related diseases, disorders and conditions; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of hypercholesteremia; Pharmaceutical preparations for the treatment of hyperlipidemia; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for the treatment of musculo-skeletal disorders; Pharmaceutical preparations for the treatment of worms in pets; Pharmaceutical preparations for the treatment of disorders of the nervous system including central nervous system (CNS) and peripheral nervous system (PNS), peripheral nerve disorders, and mental, neurological, psychological, psychosomatic, posttraumatic stress, alcohol, nicotine, and drug dependence related diseases, disorders and conditions; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for treating and preventing tendon and muscle injuries and disorders, sports related injuries, and for knee cartilage regeneration; Pharmaceutical preparations for treating chemical imbalances; Pharmaceutical preparations for treating dandruff; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for treating sunburn; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in urology; Pharmaceutical preparations for wounds; Pharmaceutical preparations of disorders of the nervous system including central nervous system (CNS) and peripheral nervous system (PNS), peripheral nerve disorders, and mental, neurological, psychological, psychosomatic, posttraumatic stress, alcohol, nicotine, and drug dependence related diseases, disorders and conditions; Pharmaceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparations, namely, a topical preparation for the treatment of ocular disorders prescribed by ophthalmologists, eye surgeons, and optometrists; Pharmaceutical preparations, namely, an analgesic for human consumption taken orally; Pharmaceutical preparations, namely, anticoagulants; Pharmaceutical preparations, namely, antidepressants; Pharmaceutical preparations, namely, appetite suppressants; Pharmaceutical preparations, namely, dantrolene sodium for injection; Pharmaceutical preparations, namely, elixirs for the treatment of disorders of the nervous system including central nervous system (CNS) and peripheral nervous system (PNS), peripheral nerve disorders, and mental, neurological, psychological, psychosomatic, posttraumatic stress, alcohol, nicotine, and drug dependence related diseases, disorders and conditions; Pharmaceutical preparations, namely, injectable contraceptives; Pharmaceutical products and preparations against dry skin caused by pregnancy; Pharmaceutical products and preparations for chloasma; Pharmaceutical products and preparations for hydrating the skin during pregnancy; Pharmaceutical products and preparations for pregnancy blemishes; Pharmaceutical products and preparations for preventing skin blemishes during pregnancy; Pharmaceutical products and preparations to prevent stretch marks; Pharmaceutical products and preparations to prevent swelling in the legs; Pharmaceutical products for ophthalmological use; Pharmaceutical products for skin care for animals; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for the treatment of joint disease; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical products for treating respiratory diseases; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical skin lotions; Pharmaceutical solutions used in dialysis; Pharmaceuticals for the treatment of erectile dysfunction; Pharmaceuticals, namely, anti-infectives; Pharmaceuticals, namely, antihelmintics; Pharmaceuticals, namely, inducers of erections; Pharmaceuticals, namely, lipid lowering agents; Pharmaceuticals, namely, psychotropics; Preparations for the suppression of hormones; Preparations for the treatment of asthma; Preparations for the treatment of burns; Preparations for treating colds; Preparations in the form of granules and liquids for controlling and removing moss; Preparations in the form of powders for controlling and removing moss; Preparations to destroy mildew; Preparations to prevent chewing or biting by animals; Preparations to prevent nail-biting and thumb-sucking; Prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets and pharmaceutical preparations for the treatment of cardiovascular disorders

Filing History

CANCELLED SEC. 8 (6-YR)
Jul 25, 2025 C8..
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Jan 15, 2024 REM1
REVIEW OF CORRESPONDENCE COMPLETE - INFORMATION MADE OF RECORD
Jun 11, 2020 CORV
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
May 13, 2020 APRE
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Mar 8, 2020 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 8, 2020 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Mar 8, 2020 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 8, 2020 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 8, 2020 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Mar 8, 2020 COAR
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Aug 7, 2019 ASGN
REGISTERED-PRINCIPAL REGISTER
Jan 15, 2019 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Dec 11, 2018 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Dec 8, 2018 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Dec 1, 2018 SUPC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Dec 1, 2018 AITU
USE AMENDMENT FILED
Nov 14, 2018 IUAF
TEAS STATEMENT OF USE RECEIVED
Nov 14, 2018 EISU
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 16, 2018 EXRA
SOU EXTENSION 1 GRANTED
May 14, 2018 EX1G
SOU EXTENSION 1 FILED
May 14, 2018 EXT1
SOU TEAS EXTENSION RECEIVED
May 14, 2018 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Nov 14, 2017 NOAM
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Sep 27, 2017 TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Sep 26, 2017 TCCA
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 19, 2017 NPUB
PUBLISHED FOR OPPOSITION
Sep 19, 2017 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 30, 2017 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 12, 2017 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 24, 2017 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 24, 2017 CRFA
ASSIGNED TO LIE
Jul 18, 2017 ALIE
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Jun 11, 2017 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
May 1, 2017 GNFN
FINAL REFUSAL E-MAILED
May 1, 2017 GNFR
FINAL REFUSAL WRITTEN
May 1, 2017 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 27, 2017 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 27, 2017 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 27, 2017 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 16, 2017 GNRN
NON-FINAL ACTION E-MAILED
Jan 16, 2017 GNRT
NON-FINAL ACTION WRITTEN
Jan 16, 2017 CNRT
ASSIGNED TO EXAMINER
Jan 13, 2017 DOCK
TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED
Oct 17, 2016 TAEA
TEAS VOLUNTARY AMENDMENT RECEIVED
Oct 17, 2016 PARI
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 13, 2016 NWOS
NEW APPLICATION ENTERED
Oct 10, 2016 NWAP